Table 1 Clinical features, disease state, response in the clinic and in vitro of patient-obtained leukemia treated with pancratistatin.
Patient # | Age | Clinical Diagnosis | % Blasts | Clinical Response | Exposure | % Apoptosis |
|---|---|---|---|---|---|---|
1 | 60 | AML - M3 | 85% | censored | 24 h | 64.9 ± 4.2 |
2 | 81 | AML-M2 | 20% | NR | 24 h | 33.5 ± 7.7 |
3 | 53 | AMoL-M5a | 96% | CR | 24 h | 46.5 ± 7.9 |
4 | 73 | CML | 9% | censored | 24 h | 63.9 ± 2.2 |
5 | 23 | AML-M5a | 70% | NR | 24 h | 30.6 ± 1.6 |
6 | 66 | ALL-L3 | 34% | NR | 48 h | 61.8 ± 9.8 |
7 | 62 | CMML-M4 | 32% | NR | 48 h | 17.7 ± 2.7 |
8 | 74 | AML-M2 | 60% | NR | 48 h | 48.6 ± 6.7 |
9 | 45 | AML | 84% | censored | 48 h | 63.9 ± 4.2 |
10 | 57 | AML-M3 | 43% | PR | 48 h | 70.8 ± 5.9 |
11 | 68 | AML-M2 | n/a | CR | 48 h | 46.8 ± 12.2 |
12 | 80 | Mantel cell lymphoma | 0% | censored | 48 h | 35.2 ± 6.6 |
13 | 47 | AML | 44% | censored | 48 h | 37.3 ± 7.7 |
14 | 71 | AML-M0, relapsed | 52% | relapsed | 48 h | 45.3 ± 11.3 |
15 | 65 | AML-MDS, relapsed | 48% | CR | 48 h | 37.3 ± 8.5 |